Where does your enterprise stand on the AI adoption curve? Take our AI survey to find out.

NGM Biopharmaceuticals, a medical startup looking to treat metabolic disorders like type 2 diabetes, has brought in an undisclosed amount of capital toward its goal of a $51 million second round of funding. Based in South San Francisco, the company is backed by the Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.


VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member